<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmacotherapy</journal-id><journal-id journal-id-type="iso-abbrev">Pharmacotherapy</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Pharmacotherapy</journal-title></journal-title-group><issn pub-type="ppub">0277-0008</issn><issn pub-type="epub">1875-9114</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11521574</article-id><article-id pub-id-type="pmcid-ver">PMC11521574.1</article-id><article-id pub-id-type="pmcaid">11521574</article-id><article-id pub-id-type="pmcaiid">11521574</article-id><article-id pub-id-type="manuscript-id">NIHMS2027872</article-id><article-id pub-id-type="pmid">39415648</article-id><article-id pub-id-type="doi">10.1002/phar.4616</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS2027872</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA2027872</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Neurodevelopmental Outcomes in Children Prenatally Exposed to Opioid Maintenance Treatment: A population-based study</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0009-0006-6604-063X</contrib-id><name name-style="western"><surname>Hasan</surname><given-names initials="M">Mennatullah</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Meador</surname><given-names initials="KJ">Kimford J.</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-1799-7233</contrib-id><name name-style="western"><surname>Brothers</surname><given-names initials="TN">Todd N.</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="S">Shuang</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-8706-1409</contrib-id><name name-style="western"><surname>Lewkowitz</surname><given-names initials="AK">Adam K</given-names></name><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-6720-3035</contrib-id><name name-style="western"><surname>Ward</surname><given-names initials="KE">Kristina E.</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-6831-7520</contrib-id><name name-style="western"><surname>Slaughter</surname><given-names initials="JL">Jonathan L.</given-names></name><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="Y">Yichi</given-names></name><xref rid="A5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-4803-7895</contrib-id><name name-style="western"><surname>Wen</surname><given-names initials="X">Xuerong</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib></contrib-group><aff id="A1"><label>1</label>Pharmacy Practice, College of Pharmacy, University of Rhode Island, Kingston, Rhode Island, USA</aff><aff id="A2"><label>2</label>Department of Neurology, Stanford University, Stanford, California, USA</aff><aff id="A3"><label>3</label>Maternal Fetal Medicine, Women and Infants Hospital of Rhode Island, Alpert Medical School of Brown University, Providence, Rhode Island, USA</aff><aff id="A4"><label>4</label>Nationwide Children&#8217;s Hospital and The Ohio State College of Medicine, Columbus, Ohio, USA</aff><aff id="A5"><label>5</label>Department of Computer Science and Statistics, University of Rhode Island, Kingston, Rhode Island, USA</aff><author-notes><corresp id="CR1"><bold>Corresponding author</bold>: Xuerong Wen, Associate Professor of Pharmacoepidemiology and Health Outcomes, University of Rhode Island, College of Pharmacy, Department of Pharmacy Practice, 7 Greenhouse Road, Suite 265F, Kingston, RI, USA 02881, <email>xuerongwen@uri.edu</email></corresp></author-notes><pub-date pub-type="ppub"><month>10</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>17</day><month>10</month><year>2024</year></pub-date><volume>44</volume><issue>10</issue><issue-id pub-id-type="pmc-issue-id">473805</issue-id><fpage>770</fpage><lpage>781</lpage><pub-history><event event-type="nihms-submitted"><date><day>24</day><month>10</month><year>2024</year></date></event><event event-type="pmc-release"><date><day>17</day><month>10</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-10-31 09:25:50.417"><day>31</day><month>10</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-2027872.pdf"/><abstract id="ABS1"><sec id="S1"><title>Background and Objectives</title><p id="P1">Opioid maintenance treatment (OMT), with methadone or buprenorphine, is a key approach for managing opioid use disorder (OUD) during pregnancy. Despite buprenorphine&#8217;s superior short-term outcomes, its long-term effects remain understudied. This study aims to evaluate the effects of prenatal OMT exposure on the incidence of childhood neurodevelopmental disorders (NDDs) considering timing effect.</p></sec><sec id="S2"><title>Methods</title><p id="P2">A retrospective cohort study using Rhode Island Medicaid data linked to vital statistics from 2008 to 2018 was conducted. The study included pregnancies having live birth from 2008 to 2016 with continuous Medicaid insurance and OUD diagnosis within 3 months preceding conception until delivery. At least one buprenorphine dispensing or a claim of methadone was required for exposure definition. Exposure was evaluated during early (0&#8211;90 days) or late (&gt;90 days) gestation, or at any pregnancy phase. NDDs, including autism, attention-deficit/hyperactivity disorder (ADHD), learning disabilities, speech/language disorders, developmental coordination disorder, intellectual disability, and behavioral disorders, were identified using validated algorithms. Applying Cox proportional-hazard models with propensity score overlap weighting, adjusted hazard ratios (aHR) were calculated, mitigating potential confounders. Children were followed up from birth until NDD diagnosis, disenrollment, or study end.</p></sec><sec id="S3"><title>Results</title><p id="P3">Of 416 mother-child dyads with OUD, 40% used methadone and 20% had buprenorphine exposure during pregnancy. NDDs were observed in 36% of children with early methadone exposure compared to 17% in the early buprenorphine exposed group (aHR: 2.75; 95% confidence interval (CI): 1.42&#8211;5.35). Further comparison to late buprenorphine exposure, late methadone exposure was associated with higher NDD risk (aHR: 2.05; 95% CI: 1.09&#8211;3.86). Compared to unexposed group, children exposed to methadone during early and late periods showed higher NDD incidences (aHR: 2.33; 95% CI: 1.51&#8211;3.60 and aHR: 2.42; 95% CI: 1.54&#8211;3.80, respectively).</p></sec><sec id="S4"><title>Discussion</title><p id="P4">The study suggests that buprenorphine is a good treatment option for OUD during pregnancy due to minimal long-term neurodevelopmental impacts on children. However, further extensive research is necessary to rule-out potential confounding.</p></sec></abstract><kwd-group><kwd>Neurodevelopmental outcomes</kwd><kwd>Opioid maintenance treatment</kwd><kwd>Methadone</kwd><kwd>Buprenorphine</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-exception-type</meta-name><meta-value>EMBARGO</meta-value></custom-meta><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>4</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>no</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>